Sanofi’s Qfitlia and Cablivi get nod from China

Sanofi (SNY) has received Chinese regulatory approval for two rare hematology drugs, Qfitlia and Cablivi, significantly ...

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs

Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...
TipRanks on MSN

Sanofi says Qfitlia, Cablivi approved in China for rare hematologic diseases

The National Medical Products Administration in China has approved two Sanofi (SNY) medicines for rare hematologic diseases: Qfitlia for ...
Medical Dialogues

Sanofi gets approval for 2 rare hematologic diseases medicines in China

With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...
Investing.com South Africa

Sanofi secures approval for two bleeding disorder treatments in China

Investing.com -- Sanofi has received approval for two bleeding disorder treatments in China, expanding its hematology portfolio in the country. The French pharmaceutical company announced Thursday ...
Pharmabiz

China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura

China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...
Becker's Hospital Review

Sanofi Promise Warranty Program for Cablivi® (caplacizumab-yhdp) Seeks to Help Support Physicians Managing aTTP

At Sanofi, we are committed to supporting the aTTP community and the health care providers who treat them. As part of this commitment, we have launched the Sanofi Promise Warranty Program for Cablivi ...
Yahoo Finance

CABLIVI Market Reports Positive Growth - Strong Momentum Expected to Continue | DelveInsight

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...
pharmaphorum

Sanofi’s rare disease drug Cablivi approved in the EU

The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which is also ...
NJBIZ

FDA approves Sanofi’s Cablivi for adults with a rare blood disorder

The U.S. Food and Drug has approved Cablivi (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) a ...
Monthly Prescribing Reference

Cablivi Approved for Acquired Thrombotic Thrombocytopenic Purpura

Sanofi announced that the Food and Drug Administration (FDA) has approved Cablivi (caplacizumab-yhdp) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in ...